Royalty Pharma Set for Upcoming Dividend Payment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 05 2026
0mins
Should l Buy RPRX?
Source: NASDAQ.COM
- Dividend Payment Overview: Royalty Pharma plc is set to go ex-dividend on February 20, 2026, with a dividend of $0.235 per share, which is expected to attract investor attention and potentially drive the stock price higher.
- Historical Performance Analysis: In the last four dividend payments, RPRX's stock price increased by $5.01 in the two weeks leading up to the ex-dividend date, indicating the potential effects of a Dividend Run and reflecting investor confidence in the stock.
- Investment Strategy Discussion: Investors have varying views on the timeframe for capturing Dividend Run effects, with some opting to buy and hold for two weeks before the ex-dividend date, while others prefer to sell the day before to maximize capital gains.
- Yield Expectations: With an implied annualized yield of 2.15%, RPRX stands out as an attractive option for dividend-focused investors, especially in the current market environment where stable dividend payments may draw more capital inflows.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RPRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RPRX
Wall Street analysts forecast RPRX stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 45.840
Low
45.00
Averages
46.50
High
48.00
Current: 45.840
Low
45.00
Averages
46.50
High
48.00
About RPRX
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. It collaborates with innovators from academic institutions, research hospitals and non-profits from small and mid-cap biotechnology companies to global pharmaceutical companies. It funds innovation in the biopharmaceutical industry both directly and indirectly. Directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties. Indirectly when it acquires existing royalties from the original innovators. Its portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, Johnson & Johnson’s Tremfya, GSK’s Trelegy, Roche’s Evrysdi, Servier’s Voranigo, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, and Gilead’s Trodelvy, among others, and 20 development-stage product candidates.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Zymeworks Secures $250 Million Royalty Financing from Royalty Pharma
- Financing Agreement Details: Zymeworks has entered into a $250 million non-recourse financing agreement with Royalty Pharma, secured by future royalties, showcasing Zymeworks' flexibility and innovation in capital raising.
- Royalty Structure: The agreement is backed by 30% of global tiered royalties from Jazz Pharmaceuticals and BeOne Medicines, ensuring stability and predictability in Zymeworks' future revenue streams.
- Repayment Terms: Royalty Pharma will receive cumulative payments of 1.65 times the note amount by December 31, 2033, or 1.925 times thereafter, indicating a longer repayment period that alleviates short-term financial pressure on Zymeworks.
- Milestone Payments Retention: Zymeworks retains full rights to regulatory and commercial milestone payments under agreements with Jazz and BeOne, with potential remaining milestone payments up to $1.5 billion, further enhancing the company's financial flexibility and growth prospects.
See More
Zymeworks Secures $250 Million Royalty-Backed Financing
- Financing Agreement Details: Zymeworks has entered into a deal with Royalty Pharma to secure $250 million through a non-recourse royalty-backed note, with repayments tied to 30% of worldwide royalties from Ziihera sales, which is expected to enhance the company's financial flexibility.
- Royalty Distribution: Under the agreement, Zymeworks will retain 70% of royalties from Ziihera sales during the repayment period, with full royalty rights reverting to Zymeworks once repayments are complete, ensuring future revenue growth for the company.
- Use of Funds: This financing will provide Zymeworks with non-dilutive capital to support its stock repurchase program, potential strategic acquisitions, and cash runway beyond 2028, which is anticipated to enhance long-term shareholder value.
- Market Outlook: Ziihera, as a treatment for HER2-positive cancers, holds significant market potential, and Zymeworks' financing will facilitate further development in this area, addressing the urgent need for new treatment options for patients.
See More
Zymeworks Secures $250 Million Royalty-Backed Financing
- Financing Agreement Details: Zymeworks has entered into a $250 million non-recourse royalty-backed note financing agreement with Royalty Pharma, with repayments tied to 30% of worldwide royalties from Ziihera sales, which is expected to significantly enhance the company's financial flexibility.
- Royalty Allocation: Under the agreement, Zymeworks will retain 70% of royalties from Ziihera sales during the repayment period, with full royalty rights reverting to Zymeworks once repayments are complete, thereby securing future revenue growth for the company.
- Capital Utilization Plans: This financing provides Zymeworks with non-dilutive capital to support its stock repurchase program and potential strategic acquisitions, extending the company's cash runway beyond 2028, which is anticipated to enhance long-term shareholder value.
- Market Outlook: Ziihera, a bispecific HER2 antibody, has the potential to transform the treatment landscape for patients with HER2-positive gastric and biliary tract cancers, and Zymeworks' financing will facilitate further development and market promotion in this area.
See More
Teva and Medincell's NDA for Long-Acting Olanzapine Accepted by FDA
- NDA Acceptance: Teva and Medincell announced that the FDA has accepted their New Drug Application for the long-acting antipsychotic olanzapine, TEV-'749, which aims to provide a more convenient treatment option for schizophrenia patients.
- Clinical Trial Validation: The NDA is supported by data from the Phase 3 SOLARIS trial, demonstrating that patients receiving TEV-'749 do not require post-administration monitoring, significantly reducing treatment burdens while aligning with the safety profile of existing olanzapine formulations.
- Addressing Market Needs: Teva's Chief Medical Officer Eric Hughes emphasized that the lack of viable long-acting olanzapine formulations has limited treatment options for patients, and the introduction of TEV-'749 will fill this care gap and enhance patient quality of life.
- Regulatory Collaboration Outlook: Teva looks forward to collaborating with the FDA on the review of TEV-'749, which, if approved, will offer a once-monthly subcutaneous injection, simplifying the current three-hour monitoring requirement and improving treatment convenience.
See More
Royalty Pharma Reports Landmark 2025 Earnings with Strong Growth and Strategic Developments
- Significant Growth: Royalty Pharma reported a 15.8% return on invested capital in Q4 2025 and a 22.8% annual return, indicating successful capital allocation that is expected to enhance its competitive position in the market.
- Capital Deployment and Returns: The company deployed $2.6 billion in capital in 2025 and returned $1.2 billion through buybacks and over $500 million in dividends, showcasing its strong cash flow and commitment to shareholder returns.
- Innovation in Synthetic Royalties: In 2025, Royalty Pharma completed four synthetic royalty transactions totaling over $2 billion, setting a record and highlighting management's focus on this funding modality as a key growth driver.
- Optimistic Outlook: The CFO projected a 3% to 8% growth in royalty receipts for 2026, targeting portfolio receipts between $3.275 billion and $3.425 billion, reflecting confidence in future growth despite facing certain challenges.
See More
Royalty Pharma Releases 2026 Financial Guidance
- Q4 Net Income: Royalty Pharma reported a net income of $214 million for Q4 2023, reflecting a stable performance and profitability in the market, which may enhance investor confidence.
- Annual Revenue Growth: The company achieved revenue of $622 million in Q4, marking a 4.7% year-over-year increase, indicating sustained growth in its product portfolio and heightened market demand, further solidifying its position in the biopharmaceutical sector.
- 2026 Financial Guidance: Royalty Pharma projects portfolio receipts for 2026 to be between $3.275 billion and $3.425 billion, a positive outlook that reflects the company's confidence in future growth and could attract more investor interest.
- Strategic Investment Commitment: The company has pledged $500 million to Teva to advance vitiligo treatment, showcasing its active involvement in innovative drug development, which may yield long-term revenue potential for Royalty Pharma.
See More
Zymeworks Secures $250 Million Royalty Financing from Royalty Pharma
- Financing Agreement Details: Zymeworks has entered into a $250 million non-recourse financing agreement with Royalty Pharma, secured by future royalties, showcasing Zymeworks' flexibility and innovation in capital raising.
- Royalty Structure: The agreement is backed by 30% of global tiered royalties from Jazz Pharmaceuticals and BeOne Medicines, ensuring stability and predictability in Zymeworks' future revenue streams.
- Repayment Terms: Royalty Pharma will receive cumulative payments of 1.65 times the note amount by December 31, 2033, or 1.925 times thereafter, indicating a longer repayment period that alleviates short-term financial pressure on Zymeworks.
- Milestone Payments Retention: Zymeworks retains full rights to regulatory and commercial milestone payments under agreements with Jazz and BeOne, with potential remaining milestone payments up to $1.5 billion, further enhancing the company's financial flexibility and growth prospects.
See More
Zymeworks Secures $250 Million Royalty-Backed Financing
- Financing Agreement Details: Zymeworks has entered into a deal with Royalty Pharma to secure $250 million through a non-recourse royalty-backed note, with repayments tied to 30% of worldwide royalties from Ziihera sales, which is expected to enhance the company's financial flexibility.
- Royalty Distribution: Under the agreement, Zymeworks will retain 70% of royalties from Ziihera sales during the repayment period, with full royalty rights reverting to Zymeworks once repayments are complete, ensuring future revenue growth for the company.
- Use of Funds: This financing will provide Zymeworks with non-dilutive capital to support its stock repurchase program, potential strategic acquisitions, and cash runway beyond 2028, which is anticipated to enhance long-term shareholder value.
- Market Outlook: Ziihera, as a treatment for HER2-positive cancers, holds significant market potential, and Zymeworks' financing will facilitate further development in this area, addressing the urgent need for new treatment options for patients.
See More
Zymeworks Secures $250 Million Royalty-Backed Financing
- Financing Agreement Details: Zymeworks has entered into a $250 million non-recourse royalty-backed note financing agreement with Royalty Pharma, with repayments tied to 30% of worldwide royalties from Ziihera sales, which is expected to significantly enhance the company's financial flexibility.
- Royalty Allocation: Under the agreement, Zymeworks will retain 70% of royalties from Ziihera sales during the repayment period, with full royalty rights reverting to Zymeworks once repayments are complete, thereby securing future revenue growth for the company.
- Capital Utilization Plans: This financing provides Zymeworks with non-dilutive capital to support its stock repurchase program and potential strategic acquisitions, extending the company's cash runway beyond 2028, which is anticipated to enhance long-term shareholder value.
- Market Outlook: Ziihera, a bispecific HER2 antibody, has the potential to transform the treatment landscape for patients with HER2-positive gastric and biliary tract cancers, and Zymeworks' financing will facilitate further development and market promotion in this area.
See More
Teva and Medincell's NDA for Long-Acting Olanzapine Accepted by FDA
- NDA Acceptance: Teva and Medincell announced that the FDA has accepted their New Drug Application for the long-acting antipsychotic olanzapine, TEV-'749, which aims to provide a more convenient treatment option for schizophrenia patients.
- Clinical Trial Validation: The NDA is supported by data from the Phase 3 SOLARIS trial, demonstrating that patients receiving TEV-'749 do not require post-administration monitoring, significantly reducing treatment burdens while aligning with the safety profile of existing olanzapine formulations.
- Addressing Market Needs: Teva's Chief Medical Officer Eric Hughes emphasized that the lack of viable long-acting olanzapine formulations has limited treatment options for patients, and the introduction of TEV-'749 will fill this care gap and enhance patient quality of life.
- Regulatory Collaboration Outlook: Teva looks forward to collaborating with the FDA on the review of TEV-'749, which, if approved, will offer a once-monthly subcutaneous injection, simplifying the current three-hour monitoring requirement and improving treatment convenience.
See More
Royalty Pharma Reports Landmark 2025 Earnings with Strong Growth and Strategic Developments
- Significant Growth: Royalty Pharma reported a 15.8% return on invested capital in Q4 2025 and a 22.8% annual return, indicating successful capital allocation that is expected to enhance its competitive position in the market.
- Capital Deployment and Returns: The company deployed $2.6 billion in capital in 2025 and returned $1.2 billion through buybacks and over $500 million in dividends, showcasing its strong cash flow and commitment to shareholder returns.
- Innovation in Synthetic Royalties: In 2025, Royalty Pharma completed four synthetic royalty transactions totaling over $2 billion, setting a record and highlighting management's focus on this funding modality as a key growth driver.
- Optimistic Outlook: The CFO projected a 3% to 8% growth in royalty receipts for 2026, targeting portfolio receipts between $3.275 billion and $3.425 billion, reflecting confidence in future growth despite facing certain challenges.
See More
Royalty Pharma Releases 2026 Financial Guidance
- Q4 Net Income: Royalty Pharma reported a net income of $214 million for Q4 2023, reflecting a stable performance and profitability in the market, which may enhance investor confidence.
- Annual Revenue Growth: The company achieved revenue of $622 million in Q4, marking a 4.7% year-over-year increase, indicating sustained growth in its product portfolio and heightened market demand, further solidifying its position in the biopharmaceutical sector.
- 2026 Financial Guidance: Royalty Pharma projects portfolio receipts for 2026 to be between $3.275 billion and $3.425 billion, a positive outlook that reflects the company's confidence in future growth and could attract more investor interest.
- Strategic Investment Commitment: The company has pledged $500 million to Teva to advance vitiligo treatment, showcasing its active involvement in innovative drug development, which may yield long-term revenue potential for Royalty Pharma.
See More
